Skip to content

IRIS-Coroflex NEO Cohort

Evaluation of Effectiveness and Safety of Coroflex ISAR NEO Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06177743
Acronym
IRIS Coroflex
Enrollment
1000
Registered
2023-12-20
Start date
2025-01-09
Completion date
2032-12-31
Last updated
2026-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Coronary Artery Stenosis

Keywords

percutaneous coronary intervention

Brief summary

The objective of this study is to evaluate the effectiveness and safety of Coroflex ISAR NEO stents in comparison to other drug-eluting stents (DES) in real-world practice.

Interventions

DEVICECoroflex ISAR NEO stent

Percutaneous coronary intervention with Coroflex ISAR NEO stent

Sponsors

Seung-Jung Park
Lead SponsorOTHER
The CardioVascular Research Foundation (CVRF)
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients ≥ 19 years old 2. Patients receiving Coroflex ISAR NEO stents. 3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.

Exclusion criteria

1. Patients with a mixture of other DESs 2. Terminal illness with life expectancy \<1 year. 3. Patients with cardiogenic shock

Design outcomes

Primary

MeasureTime frameDescription
the composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)12 monthsthe composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR) at 12 months post procedure. A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event is considered to have occurred if any one of several different events is observed.

Secondary

MeasureTime frameDescription
the event rate of all cause death5 years
the event rate of cardiac death5 years
the event rate of myocardial infarction5 years
the composite event rate of death, or myocardial infarction (MI)5 years
the composite event rate of cardiac death, or myocardial infarction (MI)5 years
the event rate of Target- Vessel Revascularization (TVR)5 years
the event rate of Target- lesion Revascularization (TLR)5 years
the event rate of stent thrombosis5 yearsaccording to an Academic Research Consortium (ARC) criteria
the event rate of stroke5 years
the event rate of Procedural success5 daysdefined as achievement of a final diameter stenosis of \<30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization.

Countries

South Korea

Contacts

CONTACTJung-Hee Ham, Project manager
cvcrc5@amc.seoul.kr82230104728

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 26, 2026